Brian Sullivan

VP, Corporate Development at Elevation Oncology


Brian Sullivan is the VP of Corporate Development at Elevation Oncology. Prior to joining Elevation Oncology, Brian served as the Senior Director of Corporate Development at Verastem Oncology from November 2010 to August 2019. In their role at Verastem Oncology, Brian was responsible for corporate communication strategy, investor/media relations, business development, corporate alliances, and early medical affairs and patient advocacy efforts.

During their time at Verastem Oncology, Brian helped the company raise over $500 million through three private rounds (series A-C), an IPO in January 2012, and subsequent follow-on equity, debt, and ATM offerings. Verastem Oncology built upon breakthrough research on cancer stem cells from the Whitehead and Broad Institutes of MIT/Harvard and translated it into three products in clinical evaluation for the treatment of solid tumors like mesothelioma, ovarian, NSCLC and breast cancer.

Brian conducted buy-side diligence on over 350 potential transactions. Following the diligence and acquisition of the PI3K delta/gamma inhibitor duvelisib, and subsequent approval by the FDA (COPIKTRA) in several types of leukemias and lymphomas, Brian served as Alliance Manager for the Japanese and Chinese product partnerships with Yakult Honsha and CSPC, respectively, for the development and regulatory expansion of COPIKTRA in Asia.

Brian Sullivan has a MS in Animal Science from the University of New Hampshire, with a focus in Reproductive Immunology. Brian also has a BS in Biology from the University of New Hampshire.

They work with Sheila G. Magil - VP, CMC & Quality, Joseph Ferra - Chief Financial Officer, and Siera Talbott - VP, Program Management & Strategic Alliances. Brian Sullivan reports to Shawn M. Leland, Founder & CEO.



  • VP, Corporate Development

    Current role

View in org chart